Innate Pharma continues Phase II trial with lirilumab as planned, following Data and Safety Monitoring Board recommendation

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board (“DSMB”) completed its second assessment of the EffiKIR study and recommended continuation of the trial, as planned.

As specified in the study protocol, the DMSB meets periodically to examine the safety data accumulated during progress of the trial. A DSMB is a committee of independent clinical research experts who review data in ongoing clinical trials with particular attention to safety. DSMBs are customarily established for large randomized multisite studies.

Enrolment in the study is on track, with more than 100 patients included.